Press

Alzheimer’s Disease Biomarker Assay Heading for IVD Status

by Biocross | Jul 24, 2017 | News

By Labmedica International staff writers Posted on 24 Jul 2017 A clinical diagnostic kit that measures the concentration of the Alzheimer's disease blood biomarker APOEepsilon4 was unveiled at the Alzheimer’s Association Conference held in London, United Kingdom, from...

La compañía biotecnológica Biocross presentará un innovador test para la determinación en 10 minutos del riesgo de desarrollar la enfermedad de Alzheimer

by Biocross | Jul 10, 2017 | Press release

El Alzheimer, enfermedad neurodegenerativa, afecta actualmente a 37 millones de personas en todo el mundo y se espera que la cifra aumente a 131 millones en 2050 El test de riesgo ApoE4 Blood Marker Assay es una prueba en sangre, coste-efectiva y contrastada que...

ApoE4 blood marker assay. A new non-genetic method to evaluate Alzheimer´s disease risk using clinical chemistry platforms

by Biocross | Dec 15, 2016 | Press release

Biocross was pleased to present at the 9th Clinical trials on Alzheimer’s Disease (CTAD) meeting, to be held in San Diego, the ApoE4 blood marker assay, a new non-genetic method to evaluate Alzheimer’s disease risk. To date only the presence of one or two APOE ε4...

Biocross presents at Bio-Europe 2016

by Biocross | Oct 29, 2016 | Press release

Biocross S.L., a biotechnology company focused on the development of innovative technologies for the diagnosis of Alzheimer’s disease and the identification of at-risk individuals, today announced that their Chief Executive Officer Matt Mittino will present the company’s projects at BIO-Europe 2016, the 22nd Annual International Partnering Conference, to be held Cologne, Germany from November 7–9, 2016.

Biospain 2016 – Company Presentation

by Biocross | Sep 29, 2016 | Press release

Biospain has become the main scientific, social, commercial, and industrial meeting point of the biotechnological sector and the primary platform for the international presentation of advances in Spanish biotechnology.

The Spanish entrepreneurs fighting against Alzheimer’s

by Biocross | Sep 21, 2016 | News

The diagnosis of Alzheimer’s disease is established through a series of neuropsychological tests, images obtained by MRI or CT scan, and the analysis of markers obtained by lumbar puncture.